41 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
Top Stock Reports for Eli Lilly, Danaher & Citigroup https://www.zacks.com/commentary/2220146/top-stock-reports-for-eli-lilly-danaher-citigroup?cid=CS-ZC-FT-research_daily-2220146 Feb 02, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Danaher Corporation (DHR) and Citigroup Inc. (C).
Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics https://www.zacks.com/stock/news/2221950/compared-to-estimates-lilly-lly-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2221950 Feb 06, 2024 - While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat https://www.zacks.com/stock/news/2222669/etfs-to-buy-as-mounjaro-powers-eli-lilly-s-q4-earnings-beat?cid=CS-ZC-FT-etf_news_and_commentary-2222669 Feb 07, 2024 - Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy? https://www.fool.com/investing/2024/02/12/this-unstoppable-growth-stock-just-announced-more/?source=iedfolrf0000001 Feb 12, 2024 - The drugmaker continues to impress investors.
Top Stock Reports for Mastercard, SAP & CrowdStrike https://www.zacks.com/commentary/2226833/top-stock-reports-for-mastercard-sap-crowdstrike?cid=CS-ZC-FT-research_daily-2226833 Feb 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), SAP SE (SAP) and CrowdStrike Holdings, Inc. (CRWD).
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat https://www.zacks.com/stock/news/2236096/nektar-nktr-q4-loss-wider-than-expected-revenue-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2236096 Mar 05, 2024 - Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Should You Buy Red-Hot Stocks Now or Wait? https://www.zacks.com/stock/news/2237396/should-you-buy-red-hot-stocks-now-or-wait?cid=CS-ZC-FT-market_edge-2237396 Mar 07, 2024 - After a mesmerizing rally to start 2024, is it too late to buy the hottest stocks?
The Best Stocks to Invest $50,000 in Right Now https://www.fool.com/investing/2024/03/09/the-best-stocks-to-invest-50000-in-right-now/?source=iedfolrf0000001 Mar 09, 2024 - These stalwart companies can help you grow your wealth.
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH https://www.zacks.com/stock/news/2241318/madrigal-mdgl-stock-up-as-fda-approves-first-drug-for-nash?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241318 Mar 15, 2024 - Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk? https://www.fool.com/investing/2024/03/22/with-shares-near-all-time-highs-is-it-a-buy/?source=iedfolrf0000001 Mar 22, 2024 - The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.

Pages: 12345

Page 1>